- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01472016
Study of ABT-700 in Subjects With Advanced Solid Tumors
November 17, 2017 updated by: AbbVie (prior sponsor, Abbott)
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET amplification or c-Met overexpression.
ABT-700, previously known as h224G11 in publications, is an anti-c-Met antibody.
The early clinical development plan for ABT-700 is based on the activity demonstrated in preclinical models.
Up to 124 subjects will be enrolled.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
74
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject with advanced solid tumors; Dose-expansion: evidence for MET gene amplification.
- Subject must have disease: a) that is not amenable to surgical resection, or b) that has progressed or recurred despite standard therapy, or c) that has failed to respond to standard therapy, or d) for which no effective therapy exists.
- Subject cannot tolerate or must not be eligible for other approved therapeutic options with known survival advantage.
- Subjects enrolled on the combination therapy phase must satisfy the above inclusion criteria and also the following: Subjects must have inoperable, locally advanced or metastatic cancer and be eligible to receive docetaxel or FOLFIRI/cetuximab or erlotinib in combination with ABT-700.
Exclusion Criteria:
- Subject has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within a period of 21 days, or herbal therapy within 7 days prior to the first dose of ABT-700.
- Subjects with uncontrolled metastases of the central nervous system. Subjects with brain metastases are eligible provided they have shown clinical and radiographic stable disease after definitive therapy and have not used steroids for at least 1 month prior to first dose of ABT-700.
- Subject has unresolved adverse events > Grade 1 from prior anticancer therapy except for alopecia or anemia.
- Subject has had major surgery within 21 days prior to the first dose of ABT-700.
- Subjects enrolled on the combination therapy phase must not meet the above exclusion criteria and must be eligible to receive docetaxel or FOLFIRI/cetuximab or erlotinib per most current prescribing information, or at the discretion of the Investigator. Subjects with K-Ras mutation-positive colorectal cancer will be excluded from receiving FOLFIRI/cetuximab.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort A
ABT-700 will be administered by intravenous infusion at escalating dose levels in 21-day dosing cycles.
Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-700.
|
ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles.
Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
|
EXPERIMENTAL: Cohort B
ABT-700 plus docetaxel.
|
ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles.
Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.
|
EXPERIMENTAL: Cohort C
ABT-700 plus FOLFIRI/cetuximab
|
ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles.
Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
Cetuximab will be administered by intravenous infusion weekly.
|
EXPERIMENTAL: Cohort D
ABT-700 plus erlotinib
|
ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles.
Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
Erlotinib will be taken orally daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the safety and tolerability of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib
Time Frame: First cycle of treatment through 60 day follow-up visit
|
Evaluation of vital signs, clinical lab testing, physical exams and adverse event monitoring
|
First cycle of treatment through 60 day follow-up visit
|
To Evaluate the pharmacokinetics of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib
Time Frame: At each cycle of treatment through 60 days after last dose.
|
Pharmacokinetic profile of ABT-700 analyzed from blood samples
|
At each cycle of treatment through 60 days after last dose.
|
To determine the recommended Phase 2 dose for ABT-700
Time Frame: First cycle of treatment through 60 day follow-up visit
|
First cycle of treatment through 60 day follow-up visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the preliminary efficacy of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib
Time Frame: Screening through 60 day follow-up visit
|
Objective response rate (complete and partial response), progression-free survival and duration of response
|
Screening through 60 day follow-up visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Louie Naumovski, MD, AbbVie
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 6, 2011
Primary Completion (ACTUAL)
April 27, 2017
Study Completion (ACTUAL)
April 27, 2017
Study Registration Dates
First Submitted
October 14, 2011
First Submitted That Met QC Criteria
November 15, 2011
First Posted (ESTIMATE)
November 16, 2011
Study Record Updates
Last Update Posted (ACTUAL)
November 21, 2017
Last Update Submitted That Met QC Criteria
November 17, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M12-375
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
Clinical Trials on ABT-700
-
AcusphereCompletedCoronary Artery DiseaseUnited States
-
Carolina Eyecare Physicians, LLCScience in VisionRecruiting
-
Anokion SAActive, not recruitingRelapsing Remitting Multiple Sclerosis | Multiple Sclerosis (MS)United States
-
Toray Industries, IncCompletedPost-Herpetic NeuralgiaJapan
-
Prim. Prof. Dr. Oliver Findl, MBACompleted
-
OFTALVIST (Oftalmología Vistahermosa S.L)Completed
-
Millennium Pharmaceuticals, Inc.Completed
-
AcusphereCompletedChronic Obstructive Pulmonary Disease | Congestive Heart FailureUnited States
-
Advanced Vision CareClinical Research Consultants, Inc.Recruiting
-
Multack Eye CareCompleted